RHAPSODY (“Risk Assessment and ProgreSsiOn of DIabetes”), a public private consortium funded by the Innovative Medicines Initiative (IMI) and EFPIA Companies with contributions from academic institutions, has announced the launch of a project focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D), a pandemic disease, which currently affects 285 million people worldwide. Leading European experts from 20 academic institutions, 4 EFPIA pharmaceutical organizations and 2 biotech companies officially launched the IMI project RHAPSODY. Lipotype is project partner in this consortium. [/spahrefn4] Combining new and existing data with the expertise of its partners, RHAPSODY will develop novel biomarkers to refine diagnosis leading to better patient stratification, promote prevention, and support innovative drug discovery for personalized management of diabetes. Click here to read the press release of RHAPSODY.